Miragen Therapeutics Inc., of Boulder, Colo., said it raised $41 million in gross proceeds from a series C preferred stock financing, including conversion of outstanding notes. Miragen plans to use the proceeds to advance two product candidates, MRG-106 and MRG-201, into clinical development this year.